Therapy Optimization in Multiple Sclerosis

- Multiple Sclerosis
- Completed

Study Title: Therapy Optimization in Multiple Sclerosis (MS)

Teva Identifier: PM032

ClinicalTrials.gov Identifier: NCT00819000

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 12/01/2008 - 01/01/2013

Study Type

Observational